# CEPI - Coalition for Epidemic Preparedness Innovations

> Partnership globale per sviluppo vaccini contro minacce pandemiche, nata a Davos, co-architetto di COVAX

## Executive Summary

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 2017 (Davos) |
| **Sede** | Oslo, Norway |
| **Tipo** | Agency (PPP) |
| **CEO** | Dr. Richard Hatchett |
| **Funding iniziale** | $460M |
| **Funding totale impegnato** | $3.1B |
| **Target** | Vaccini in 100 giorni (vs 300 per COVID) |
| **Status** | Active |

---

## Glossario

| Termine | Definizione |
|---------|-------------|
| **100 Days Mission** | Obiettivo sviluppare vaccini in 100 giorni da identificazione patogeno |
| **COVAX** | COVID-19 Vaccines Global Access - co-fondato da CEPI |
| **Disease X** | Patogeno sconosciuto con potenziale pandemico |
| **R&D Blueprint** | Lista WHO di patogeni prioritari |

---

## Fondazione e Storia

| Dato | Dettaglio |
|------|-----------|
| **Fondazione** | Gennaio 2017, World Economic Forum Davos |
| **Fondatori** | Gates Foundation, Wellcome Trust, governi (Norvegia, Giappone, Germania) |
| **Contesto** | Post-Ebola 2014-16, necessita' accelerare sviluppo vaccini |
| **Obiettivo dichiarato** | "To accelerate development of vaccines against emerging infectious diseases" |

### Timeline Storica

| Anno | Evento |
|------|--------|
| **2017** | Lancio a Davos con $460M iniziali |
| **2017** | Richard Hatchett diventa CEO |
| **2020** | COVAX co-fondato con GAVI e WHO |
| **2020** | Finanzia sviluppo vaccini COVID (AstraZeneca, Moderna, Novavax) |
| **2022** | 100 Days Mission lanciata |
| **2024** | $145M a BioNTech per facility Rwanda |
| **2024** | Biosecurity Strategy lanciata |

---

## Struttura e Governance

### Leadership

| Ruolo | Nome | Dal | Background |
|-------|------|-----|------------|
| CEO | [Dr. Richard Hatchett](../persons/richard-hatchett.md) | 2017 | Ex-BARDA, NSC Obama, HSC Bush |
| Chair | [Jane Halton](../persons/jane-halton.md) | 2017 | Ex-Secretary Health Australia |
| Vice-Chair | [Githinji Gitahi](../persons/githinji-gitahi.md) | 2025 | CEO Amref Health Africa, Chair Equitable Access Committee, Co-Chair UHC2030 |

### Board Members (2025)

| Nome | Tipo | Paese | Ruolo/Background |
|------|------|-------|------------------|
| [Soumya Swaminathan](../persons/soumya-swaminathan.md) | Independent | IND | Ex-WHO Chief Scientist (2019-2023), Chair MSSRF, figlia di M.S. Swaminathan |
| [Yasuhiro Suzuki](../persons/yasuhiro-suzuki.md) | Investor Rep | JPN | Ex-Vice-Minister Health Japan, Ex-WHO Executive Director (1998-2002), President IUHW |
| [Samba Sow](../persons/samba-sow.md) | Independent | MLI | Director General CVD-Mali (2001-), ex-Minister Health Mali (2017-2019), WHO Special Envoy COVID-19 West Africa, Legion d'Onore |
| [Anita Zaidi](../persons/anita-zaidi.md) | Independent | PAK-USA | Gates Foundation President Gender Equality (2022-), Director Vaccine Development (2014-2022) |
| [Juan Pablo Uribe](../persons/juan-pablo-uribe.md) | Observer | COL | World Bank Global Director Health (2021-2025), ex-Health Minister Colombia (2018-2019), now WB Division Director Central America |
| [Chikwe Ihekweazu](../persons/chikwe-ihekweazu.md) | Observer | NGA-DEU | WHO Health Emergencies (from 2025) |
| [Victor Dzau](../persons/victor-dzau.md) | Board | USA | NAM President |
| [Margaret Hamburg](../persons/margaret-hamburg.md) | Former | USA | Ex-FDA Commissioner |

### Advisory

| Ruolo | Nome | Dal |
|-------|------|-----|
| JCG Chair | [Gagandeep Kang](../persons/gagandeep-kang.md) | 2023 |

### Former Board

| Nome | Periodo | Note |
|------|---------|------|
| [Gagandeep Kang](../persons/gagandeep-kang.md) | 2018-2023 | Board member, ora JCG Chair. Gates Foundation Director (2023-), FRS 2019, "Vaccine Godmother of India" |
| [Michael Ryan](../persons/michael-ryan.md) | 2023-2025 | WHO rep (non-voting), GOARN founder, Deputy DG WHO 2024-2025, rimosso da exec team 2025 |
| [Nísia Trindade](../persons/nisia-trindade.md) | 2021-2023 | President Fiocruz (2017-2023), left to become Brazil Health Minister (2023-2025, first woman), now USP Chair |

### Richard Hatchett - Background

| Periodo | Ruolo |
|---------|-------|
| Pre-2017 | Director BARDA (US Biomedical Advanced Research and Development Authority) |
| - | Homeland Security Council (Bush) |
| - | National Security Council (Obama) |
| 2017- | CEO CEPI |

**Pattern**: Revolving door USA security/health → global health PPP.

### Fondatori e Funders

| Fondatore | Tipo | Contributo iniziale |
|-----------|------|---------------------|
| [Gates Foundation](../foundation/gates-foundation.md) | Foundation | Major |
| [Wellcome Trust](../foundation/wellcome-trust.md) | Foundation | Major |
| Norway | Government | Major |
| Japan | Government | Major |
| Germany | Government | Major |

---

## 100 Days Mission

### Obiettivo

Ridurre tempo sviluppo vaccini:
- **Pre-COVID**: 10+ anni
- **COVID**: ~300 giorni
- **Target CEPI**: 100 giorni

### Come

```
GIORNO 0: Identificazione patogeno
        |
        v
GIORNO 30: Candidati vaccino selezionati
        |
        v
GIORNO 60: Trial clinici fase 1/2
        |
        v
GIORNO 100: Vaccino pronto per produzione
```

### Piattaforme Tecnologiche

| Piattaforma | Partner | Status |
|-------------|---------|--------|
| mRNA | BioNTech, Moderna | Validated (COVID) |
| Viral vector | AstraZeneca, J&J | Validated |
| Protein subunit | Novavax | Validated |

---

## COVAX

| Metrica | Valore |
|---------|--------|
| **Lanciato** | 2020 |
| **Partner** | CEPI (R&D), GAVI (procurement), WHO (policy) |
| **Dosi distribuite** | 2B+ |
| **Paesi serviti** | 146 |

### Ruolo CEPI in COVAX

```
COVAX STRUCTURE
        |
        +-- CEPI (R&D pillar)
        |   |
        |   +-- Finanzia sviluppo vaccini
        |   +-- De-risk per pharma
        |   +-- Diversifica portfolio
        |
        +-- GAVI (Procurement pillar)
        |   |
        |   +-- Acquista dosi
        |   +-- Distribuisce
        |
        +-- WHO (Policy pillar)
            |
            +-- Allocation framework
            +-- Regulatory guidance
```

---

## Investimenti 2024

| Target | Importo | Scopo |
|--------|---------|-------|
| BioNTech | $145M | Facility mRNA Kigali, Rwanda |
| Valneva | EU co-funding | Vaccino chikungunya |

### Pattern Africa Manufacturing

CEPI sta finanziando capacita' produttiva vaccini in Africa per ridurre dipendenza da import.

---

## Connessioni PowerLink

### Organizzazioni Correlate

| Organizzazione | Tipo Relazione |
|----------------|----------------|
| [Gates Foundation](../foundation/gates-foundation.md) | Co-founder, major funder |
| [Wellcome Trust](../foundation/wellcome-trust.md) | Co-founder, major funder |
| [GAVI](../agency/gavi.md) | Partner COVAX |
| [WHO](../agency/who.md) | Partner COVAX, R&D Blueprint |
| [WEF](../forum/wef.md) | Lanciato a Davos 2017 |
| [Amref Health Africa](../foundation/amref.md) | Vice-Chair Gitahi e' CEO |
| [CVD-Mali](../agency/cvd-mali.md) | Board member Sow e' Director |

### Figure Chiave

| Persona | Ruolo |
|---------|-------|
| [Richard Hatchett](../persons/richard-hatchett.md) | CEO |
| [Jane Halton](../persons/jane-halton.md) | Chair |
| [Githinji Gitahi](../persons/githinji-gitahi.md) | Vice-Chair, Chair Equitable Access Committee |
| [Seth Berkley](../persons/seth-berkley.md) | Co-architetto COVAX (ex-GAVI) |
| [Bill Gates](../persons/bill-gates.md) | Funder |
| [Soumya Swaminathan](../persons/soumya-swaminathan.md) | Board, ex-WHO Chief Scientist |
| [Samba Sow](../persons/samba-sow.md) | Board, Director CVD-Mali, WHO Special Envoy |
| [Anita Zaidi](../persons/anita-zaidi.md) | Board, Gates Foundation President Gender Equality |
| [Juan Pablo Uribe](../persons/juan-pablo-uribe.md) | Observer, World Bank Global Director Health |
| [Gagandeep Kang](../persons/gagandeep-kang.md) | JCG Chair, ex-Board (2018-2023), Gates Foundation Director |

### Pharma Partners

| Azienda | Relazione |
|---------|-----------|
| [AstraZeneca](../company/astrazeneca.md) | COVID vaccine funded |
| [Moderna](../company/moderna.md) | COVID vaccine funded |
| Novavax | COVID vaccine funded |
| [BioNTech](../company/biontech.md) | Africa manufacturing |
| Valneva | Chikungunya vaccine |

---

## Pattern Identificati

### 1. Davos Origin

CEPI e' stata formalmente lanciata al WEF Davos 2017 - esempio di forum transnazionale come incubatore di istituzioni globali.

### 2. PPP Model

```
GOVERNI (Norvegia, Giappone, Germania)
        |
        +-- Funding pubblico
        |
FONDAZIONI (Gates, Wellcome)
        |
        +-- Funding privato
        +-- Expertise
        |
PHARMA
        |
        +-- R&D, manufacturing
        +-- De-risked da CEPI funding
        |
        v
    CEPI (coordina)
```

### 3. Revolving Door USA

Hatchett: BARDA → NSC → HSC → CEPI

Pattern di ufficiali US security/health che passano a ruoli globali.

### 4. COVID come Proof of Concept

COVID ha validato il modello CEPI:
- Vaccini sviluppati in tempo record
- Piattaforme (mRNA) ora standard
- Ma anche critiche su equita' distribuzione

---

## Critiche

| Tema | Dettaglio |
|------|-----------|
| **Equity gaps** | Paesi ricchi hanno avuto vaccini prima |
| **IP protection** | Non ha sostenuto waiver brevetti |
| **Pharma dependency** | De-risk pubblico, profitti privati |
| **Governance opaca** | Dominata da fondazioni occidentali |

---

## Fonti

### Ufficiali
- [CEPI Official](https://cepi.net/)
- [CEPI About](https://cepi.net/about-cepi)

### Wikipedia
- [Wikipedia - CEPI](https://en.wikipedia.org/wiki/Coalition_for_Epidemic_Preparedness_Innovations)

### Analisi
- [McKinsey - Interview Richard Hatchett](https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-pandemic-response-efforts-an-interview-with-cepis-richard-hatchett)
- [Council on Strategic Risks - CEPI Biosecurity Strategy](https://councilonstrategicrisks.org/2024/10/07/a-new-biosecurity-strategy-for-the-world-to-follow/)

---

*Ultimo aggiornamento: Febbraio 2026*
